GUTS Stock Summary and Trading Ideas (Fractyl Health | NASDAQ:GUTS)

Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

Fractyl Health trades on the NASDAQ stock market under the symbol GUTS.

As of August 18, 2026, GUTS stock price climbed to $0.72 with 1,504,430 million shares trading.

GUTS has a beta of 1.96, meaning it tends to be more sensitive to market movements. GUTS has a correlation of 0.02 to the broad based SPY ETF.

GUTS has a market cap of $114.15 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that GUTS belongs to (by Net Assets): VTI, VXF.

GUTS has underperformed the market in the last year with a return of -29.7%, while the SPY ETF gained +20.4%. In the last 3 month period, GUTS fell short of the market, returning -16.7%, while SPY returned +4.1%. However, in the most recent 2 weeks GUTS has outperformed the stock market by returning +5.9%, while SPY returned +1.3%.

GUTS support price is $.63 and resistance is $.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GUTS shares will trade within this expected range on the day.